Cigna Research Reveals Less Than 1 in 3 Americans Have Strong Sense of Purpose
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 day ago0mins
- Purpose and Health: Cigna's research indicates that individuals with a strong sense of purpose report significantly higher vitality, better health, stronger relationships, and greater work engagement; however, the 2025 Vitality in America report reveals that fewer than one in three American adults claim to have a strong sense of purpose.
- Social Impact: This finding highlights a widespread lack of purpose among American adults, which could adversely affect overall societal health and work efficiency, suggesting a need for businesses and policymakers to focus on enhancing mental health and sense of purpose.
- Research Background: The report is based on a comprehensive survey of American adults aimed at revealing the impact of purpose on personal quality of life, emphasizing the importance of mental health in modern society.
- Future Outlook: Cigna may leverage these findings to promote related health initiatives aimed at enhancing public sense of purpose and quality of life, thereby strengthening its competitive position in the health insurance market.
CI.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 270.320
Low
294.00
Averages
337.60
High
378.00
Current: 270.320
Low
294.00
Averages
337.60
High
378.00
Guggenheim
Buy
maintain
$309 -> $318
2025-12-02
New
Reason
Guggenheim
Price Target
$309 -> $318
2025-12-02
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Cigna to $318 from $309 and keeps a Buy rating on the shares.
BofA
initiated
2025-11-19
Reason
BofA
Price Target
2025-11-19
initiated
Reason
BofA analysts added Cigna to the firm's "US 1 List," which represents a collection of its best investment ideas.
Bernstein
Lance Wilkes
Market Perform
downgrade
$346 -> $294
2025-11-12
Reason
Bernstein
Lance Wilkes
Price Target
$346 -> $294
2025-11-12
downgrade
Market Perform
Reason
Bernstein analyst Lance Wilkes lowered the firm's price target on Cigna to $294 from $346 and keeps a Market Perform rating on the shares following quarterly results. The firm is also adjusting its EPS model to reflect pressure in the PBM margin, with 2026 Evernorth earnings expected down 4% due to Pharmacy Benefit Services subsegment margin declining by an estimated 17%, offset by growth in the specialty segment and Cigna Healthcare.
Goldman Sachs
Scott Fidel
Buy
downgrade
$370 -> $330
2025-11-05
Reason
Goldman Sachs
Scott Fidel
Price Target
$370 -> $330
2025-11-05
downgrade
Buy
Reason
Goldman Sachs analyst Scott Fidel lowered the firm's price target on Cigna to $330 from $370 and keeps a Buy rating on the shares.
See All Ratings
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why does Trump oppose extending subsidies for the Affordable Care Act?
What are the key concerns of Republican lawmakers regarding ACA reform?
How might Trump's alternative healthcare proposal impact individual insurance buyers?
What could be the political consequences of the ACA subsidy debate?